Skip to main content

QGEN · Qiagen N.V.

Track QGEN — free
$45.86 +1.11 (+2.48%)
Market Cap
$9.12B
Shares
206.50M
Volume · Oct 5 1.76M Avg daily vol (3M) 2.75M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$44.75 Open$42.45 Day$42.18–45.60 52W close$32.63–55.66 Avg vol 30d2.3M Short int7.7M · 3.7% float · 4.5d Short vol61% Last earningsAug 6, 2026 DataJan 2020–Oct 2026

Up next

Next earnings call
Nov 10, 2026 Est · unconfirmed · in 5 wks
call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+5.7%
Year over year
Operating margin
22.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.6%
Year over year · fewer shares
Price change (1Y)
-3.2%
Trailing year
Short interest
3.7%
Latest settlement · 4.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +5%
above
Price vs 50-day avg +4%
above
RSI (14) 55
neutral
MACD trend Negative
52-week position 53%
mid-range
Momentum
relative strength
Strong
1-month return +2%
trailing
6-month return +7%
trailing
YTD return 0%
this year
Relative strength −5%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $43 › 200d $42 — 50d above 200d
Institutional flow Accumulating
2 of 341 funds reported for Sep 30 · net +1.3K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.71% of float · ▲ +2.1% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
341 holders — mid 3-yr range
Squeeze score 71
high risk · 0–100
Fundamentals
Excellent
Revenue growth +6%
Y/Y
Gross margin 62%
expanding
EPS growth +424%
Y/Y
Free cash flow $453.3M
Buyback $100.0M
authorized
Balance sheet $815.4M
net debt
Quant / Vol
risk profile
High
Volatility 36%
annualized · 1-yr
Max drawdown −41%
past year
ATR 3.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 30, 2026
Total net sales growth · the third quarter 1% – 2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+5% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
55 Neutral
MACD trend
Negative Bearish
52-week position
53% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $43 › 200d $42 — 50d above 200d
Institutional flow Accumulating
2 of 341 funds reported for Sep 30 · net +1.3K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.71% of float · ▲ +2.1% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
341 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $33 Now $45 · 53% Range high $56
vs 200-day avg +5% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
QGEN
Qiagen N.V.
this stock
$9.12B -0.5% +5.7% — 3.7%
TMO
Thermo Fisher Scientific Inc.
$249.58B +13.0% +14.5% 36.3 1.4%
DHR
Danaher Corp /De/
$150.37B -6.5% +8.5% 37.9 1.2%
NTRA
Natera, Inc.
$59.47B +79.1% -2.8% — 3.3%
A
Agilent Technologies, Inc.
$48.90B +23.3% +6.4% 34.2 1.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
342
% held
72.3%
Reported
2 of 341
Top holder
WELLINGTON MANAGEMENT GRO…
Held Float
View
Held by Funds
Fund positions
102
View
Short & Settlement
Short Interest Rising
Shares short
7.7M
Days to cover
4.5d
Change
+155.0K sh
View
Short Volume
Short vol %
61%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
28.5K
Value
$1.2M
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
40.1%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Peter Welch
Amount
$1.0K–$15.0K
Traded
Mar 24, 2020
View
Financials
Financials
Revenue (FY)
$2.1B
Net income (FY)
$424.9M
EPS diluted
$1.94
View
Buybacks
Authorized
$100.0M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 15, 2026
This year
13
View
Proposed Sales
Value
$1.2M
Shares
25.0K
Filed
Aug 15, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 6, 2026
Last webcast
Sep 22, 2026
View
Investor Relations
Latest news
QIAGEN Completes U.S. QIAstat-Dx…
Published
Sep 28, 2026
Upcoming events
4
View

Performance

5D 20D 120D MTD YTD
QGEN +1.3% +2.0% +6.8% +2.3% -0.5%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY +1.5% +2.5% -5.4% +1.3% -13.4%

Capital returns

Buyback program · as of Jul 12, 2021
Authorized
$100.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1015820 CUSIP N72482156 13F (30d) 6 filings 6 filers Visit website Investor relations